Spero Therapeutics(DE:2HA)
€0.90-0.03 (-3.03%)
DE:2HA
Spero Therapeutics technical analysis
€0.90
At close:-0.03 (-3.03%)
Spero Therapeutics (2HA) Technical Analysis
2 Followers
Technical Sentiment
Overall ConsensusStrong Sell Strong Buy Strong Sell
15Bearish
4Neutral
3Bullish
Technical Analysis ConsensusStrong Sell Strong Buy Neutral
3Bearish
4Neutral
3Bullish
Moving Average ConsensusStrong Sell Strong Buy Strong Sell
12Bearish
0Neutral
0Bullish
1 Day timeframe · Data as of Nov 11, 2026
- Spero Therapeutics’s (2HA) Moving Averages Convergence Divergence (MACD) indicator is -0.04, suggesting Spero Therapeutics is a Sell.
- Spero Therapeutics’s (2HA) 20-Day exponential moving average is 0.94, while Spero Therapeutics’s (2HA) share price is €0.90, making it a Sell.
- Spero Therapeutics’s (2HA) 50-Day exponential moving average is 1.05, while Spero Therapeutics’s (2HA) share price is €0.90, making it a Sell.
Spero Therapeutics (2HA) Pivot Points
1 Day timeframe · Data as of Nov 11, 2026
| Name | S3 | S2 | S1 | Pivot Points | R1 | R2 | R3 |
|---|---|---|---|---|---|---|---|
| Classic | 0.86 | 0.87 | 0.90 | 0.91 | 0.94 | 0.95 | 0.97 |
| Fibonacci | 0.87 | 0.89 | 0.90 | 0.91 | 0.93 | 0.93 | 0.95 |
Spero Therapeutics (2HA) Moving Averages
1 Day timeframe · Data as of Nov 11, 2026
| Period | Simple | Exponential |
|---|---|---|
| MA5 | 0.91Sell | 0.91Sell |
| MA10 | 0.91Sell | 0.92Sell |
| MA20 | 0.94Sell | 0.94Sell |
| MA50 | 0.99Sell | 1.05Sell |
| MA100 | 1.33Sell | 1.28Sell |
| MA200 | 1.71Sell | 1.56Sell |
- Spero Therapeutics’s (2HA) 10-Day exponential moving average is 0.92, while Spero Therapeutics’s (2HA) share price is €0.90, making it a Sell.
- Spero Therapeutics’s (2HA) 100-Day exponential moving average is 1.28, while Spero Therapeutics’s (2HA) share price is €0.90, making it a Sell.
- Spero Therapeutics’s (2HA) stock price is €0.90 and Spero Therapeutics’s (2HA) 50-day simple moving average is 0.99, creating a Sell signal.
- Spero Therapeutics’s (2HA) stock price is €0.90 and Spero Therapeutics’s (2HA) 100-day simple moving average is 1.33, creating a Sell signal.
- Spero Therapeutics’s (2HA) stock price is €0.90 and Spero Therapeutics’s (2HA) 200-day simple moving average is 1.71, creating a Sell signal.
Spero Therapeutics (2HA) Technical Indicators
1 Day timeframe · Data as of Nov 11, 2026
| Name | Value | Implied Action |
|---|---|---|
| RSI (14) | 41.67 | Neutral |
| STOCH (9,6) | 38.05 | Neutral |
| STOCHRSI (14) | 32.12 | Neutral |
| MACD (12,26) | -0.04 | Sell |
| ADX (14) | 16.66 | Buy |
| Williams %R | -68.55 | Buy |
| CCI (14) | -102.14 | Buy |
| ATR (14) | 0.07 | - |
| Ultimate Oscillator | 68.15 | Neutral |
| ROC | -11.37 | Sell |
- Spero Therapeutics’s (2HA) Relative Strength Index (RSI) is 41.67, creating a Neutral signal.
- Spero Therapeutics’s (2HA) Trend Strength Indicator (ADX) is 16.66, creating a Buy signal.
- Spero Therapeutics’s (2HA) Commodity Channel Index (CCI) is -102.14, creating a Buy signal.
- Spero Therapeutics’s (2HA) Price Rate of Change (ROC) is -11.37, creating a Sell signal.
unique trading strategy with a flexible screenerTry it Now!
FAQ
Is 2HA a Buy, Hold, or Sell?
Based on 2HA’s technical indicators on the 1-day timeframe as of Nov 11, 2026, 2HA is a Strong Sell.
What is 2HA’s RSI (14)?
2HA’s RSI (14) is 41.67, which suggests 2HA is a Neutral.
What is 2HA’s MACD?
2HA’s MACD is -0.04, which suggests 2HA is a Sell.
What is 2HA’s 5-day moving average?
2HA’s 5-day moving average is 0.91, which suggests 2HA is a Sell.
What is 2HA’s 20-day moving average?
2HA 20-day moving average is 0.94, which suggests 2HA is a Sell.
What is 2HA’s 50-day moving average?
2HA’s 50-day moving average is 0.99, which suggests 2HA is a Sell.
What is 2HA’s 200-day moving average?
2HA’s 200-day moving average is 1.71, which suggests 2HA is a Sell.
What is 2HA’s Williams % R (14)?
2HA’s Williams % R (14) is -68.55, which suggests 2HA is a Buy.
What is 2HA’s CCI (14)?
2HA’s CCI (14) is -102.14, which suggests 2HA is a Buy.
What is the share price of Spero Therapeutics?
Spero Therapeutics's share price is N/A€.

